Published in Clin Genet on January 20, 2010
Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol (2013) 1.46
Evaluation of hepatic cystic lesions. World J Gastroenterol (2013) 1.43
Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet J Rare Dis (2014) 1.35
Polycystin-1: a master regulator of intersecting cystic pathways. Trends Mol Med (2014) 0.91
Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol (2014) 0.87
Mutation of sec63 in zebrafish causes defects in myelinated axons and liver pathology. Dis Model Mech (2012) 0.86
Current management of noninfectious hepatic cystic lesions: A review of the literature. World J Hepatol (2013) 0.83
Loss of heterozygosity is present in SEC63 germline carriers with polycystic liver disease. PLoS One (2012) 0.82
microRNA biomarkers in cystic diseases. BMB Rep (2013) 0.78
Boy with autosomal recessive polycystic kidney and autosomal dominant polycystic liver disease. Pediatr Nephrol (2012) 0.75
PRKCSH GAG trinucleotide repeat is a mutational target in gastric carcinomas with high-level microsatellite instability. Clin Genet (2011) 0.75
Waitlisted Candidates With Polycystic Liver Disease are More Likely to be Transplanted Than Those With Chronic Liver Failure. Transplantation (2017) 0.75
CYP1A1 and GSTP1 gene variations in breast cancer: a systematic review and case-control study. Fam Cancer (2016) 0.75
Clustal W and Clustal X version 2.0. Bioinformatics (2007) 126.47
SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res (2003) 52.26
Human non-synonymous SNPs: server and survey. Nucleic Acids Res (2002) 50.45
Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol (1999) 33.07
The PSIPRED protein structure prediction server. Bioinformatics (2000) 20.58
Improved splice site detection in Genie. J Comput Biol (1997) 11.57
Increasing the precision of comparative models with YASARA NOVA--a self-parameterizing force field. Proteins (2002) 6.21
Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol (2004) 4.00
Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet (1994) 3.73
Sequence-based prediction of pathological mutations. Proteins (2004) 2.71
Congenital diseases of intrahepatic bile ducts: variations on the theme "ductal plate malformation". Hepatology (1992) 2.59
The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA. Nucleic Acids Res (1994) 2.37
Pathogenic or not? And if so, then how? Studying the effects of missense mutations using bioinformatics methods. Hum Mutat (2009) 2.25
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst (2001) 2.13
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Standardizing mutation nomenclature: why bother? Hum Mutat (2003) 1.80
Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet (2003) 1.77
Proof of "disease causing" mutation. Hum Mutat (1998) 1.68
Proteins of the endoplasmic-reticulum-associated degradation pathway: domain detection and function prediction. Biochem J (2000) 1.58
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet (2003) 1.47
Mammalian Sec61 is associated with Sec62 and Sec63. J Biol Chem (2000) 1.47
Clinical profile of autosomal dominant polycystic liver disease. Hepatology (2003) 1.37
Polycystic liver disease is a disorder of cotranslational protein processing. Trends Mol Med (2005) 1.28
Quaternary and domain structure of glycoprotein processing glucosidase II. Biochemistry (2001) 1.15
Isolated polycystic liver disease as a distinct genetic disease, unlinked to polycystic kidney disease 1 and polycystic kidney disease 2. Hepatology (1996) 1.12
Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease. Hum Mutat (2006) 1.10
PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation. Hum Mol Genet (2010) 1.10
Polycystic liver disease is genetically heterogeneous: clinical and linkage studies in eight Finnish families. J Hepatol (2003) 1.00
Abnormal hepatocystin caused by truncating PRKCSH mutations leads to autosomal dominant polycystic liver disease. Hepatology (2004) 0.90
Cysts of PRKCSH mutated polycystic liver disease patients lack hepatocystin but express Sec63p. Histochem Cell Biol (2008) 0.88
Autosomal dominant polycystic liver disease in a family without polycystic kidney disease associated with a novel missense protein kinase C substrate 80K-H mutation. World J Gastroenterol (2005) 0.78
A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology (2000) 9.74
PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science (1996) 6.56
Mesenteric venous thrombosis. N Engl J Med (2001) 5.87
Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc (2000) 4.45
Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell (1998) 3.84
MELD and PELD: application of survival models to liver allocation. Liver Transpl (2001) 3.76
PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet (1997) 3.58
Management of ectopic varices. Hepatology (1998) 2.88
Identification and characterization of polycystin-2, the PKD2 gene product. J Biol Chem (1999) 2.74
Getting a foothold in nephrotic syndrome. Nat Genet (2000) 2.68
The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med (1990) 2.26
Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat Genet (2000) 2.24
Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. Am J Kidney Dis (1983) 2.22
Hepatic cyst infection in autosomal dominant polycystic kidney disease. Mayo Clin Proc (1990) 2.02
Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Genomics (1995) 1.86
Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD): molecular genetics, clinical experience, and fetal morphology. Am J Med Genet (1998) 1.85
Autosomal dominant polycystic kidney disease: localization of the second gene to chromosome 4q13-q23. Genomics (1993) 1.77
Value of molecular analysis of Wilson's disease in the absence of tissue copper deposits: a novel ATP7B mutation in an adult patient. Neth J Med (2008) 1.77
Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype. J Med Genet (2009) 1.74
Nav1.7-related small fiber neuropathy: impaired slow-inactivation and DRG neuron hyperexcitability. Neurology (2012) 1.73
Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int (1988) 1.72
NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci (2008) 1.70
Cyst decompression surgery for autosomal dominant polycystic kidney disease. J Am Soc Nephrol (1992) 1.68
Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis (1998) 1.64
Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med (1999) 1.63
Nerve growth cones isolated from fetal rat brain: subcellular fractionation and characterization. Cell (1983) 1.62
Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Mol Cell (1998) 1.61
Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut (2008) 1.56
The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int (2001) 1.56
Vascular expression of polycystin. J Am Soc Nephrol (1997) 1.51
Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med (2005) 1.48
Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease. Am J Hum Genet (2001) 1.47
Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int (2007) 1.44
The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther (2011) 1.42
Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant (2001) 1.40
Hypermanganesemia, hereditary hemorrhagic telangiectasia, brain abscess: the hepatic connection. Neurology (2008) 1.40
Ascites and hepatorenal syndrome: pathophysiology and management. Mayo Clin Proc (1996) 1.39
A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation. Kidney Int (2007) 1.38
Liver resection and cyst fenestration in the treatment of severe polycystic liver disease. Gastroenterology (1995) 1.36
The polycystic kidney disease protein PKD2 interacts with Hax-1, a protein associated with the actin cytoskeleton. Proc Natl Acad Sci U S A (2000) 1.36
Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2000) 1.32
Comprehensive genomic analysis of PKHD1 mutations in ARPKD cohorts. J Med Genet (2005) 1.32
The progression of vesicoureteral reflux nephropathy. Ann Intern Med (1980) 1.31
Vascular expression of polycystin-2. J Am Soc Nephrol (2001) 1.28
Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther (2012) 1.27
Aberrant splicing in the PKD2 gene as a cause of polycystic kidney disease. J Am Soc Nephrol (1999) 1.26
Somatostatin analogues reduce liver volume in polycystic liver disease. Gut (2008) 1.25
Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (1994) 1.25
Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1. Am J Hum Genet (2000) 1.24
Treatment of highly symptomatic polycystic liver disease. Preliminary experience with a combined hepatic resection-fenestration procedure. Ann Surg (1990) 1.18
The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther (2011) 1.17
Molecular genetics and mechanism of autosomal dominant polycystic kidney disease. Mol Genet Metab (2000) 1.17
Immunolocalization of polycystin in human tissues and cultured cells. Proc Assoc Am Physicians (1996) 1.17
Renal involvement in relapsing polychondritis. Medicine (Baltimore) (1987) 1.16
Glycogenic hepatopathy: a rare cause of elevated serum transaminases in diabetes mellitus. Neth J Med (2009) 1.15
Blood pressure determinants in living-related renal allograft donors and their recipients. Kidney Int (1987) 1.15
Pharmacological management of pain in chronic pancreatitis. Dig Liver Dis (2006) 1.13
The gene for autosomal dominant polycystic kidney disease lies in a 750-kb CpG-rich region. Genomics (1992) 1.12
Renal epithelial hyperplastic and neoplastic proliferation in autosomal dominant polycystic kidney disease. Am J Kidney Dis (1987) 1.11
Linkage disequilibrium in the region of the autosomal dominant polycystic kidney disease gene (PKD1). Am J Hum Genet (1994) 1.11
Saccular intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (1992) 1.09
Modulation of cyclic nucleotides in islated rat glomeruli: role of histamine, carbamylcholine, parathyroid hormone, and angiotensin-II. J Clin Invest (1978) 1.08
Mevalonate kinase deficiency: Evidence for a phenotypic continuum. Neurology (2004) 1.08
In vivo interaction of the adapter protein CD2-associated protein with the type 2 polycystic kidney disease protein, polycystin-2. J Biol Chem (2000) 1.08
Editorial: neutrophil dysfunction in patients with cirrhosis. Aliment Pharmacol Ther (2014) 1.07
Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection. Transplantation (1988) 1.06
Motility of the ileocolonic junction. Gut (1988) 1.06
Identification of PKD2L, a human PKD2-related gene: tissue-specific expression and mapping to chromosome 10q25. Genomics (1998) 1.04
Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc (1990) 1.04
Treatment extension benefits HCV genotype 1 patients without rapid virological response: a systematic review. Neth J Med (2011) 1.04
Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. Carcinogenesis (2004) 1.04
A spectrum of mutations in the second gene for autosomal dominant polycystic kidney disease (PKD2). Am J Hum Genet (1997) 1.04
On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis (2011) 1.04
The risks of unilateral nephrectomy: status of kidney donors 10 to 20 years postoperatively. Mayo Clin Proc (1985) 1.03
Polycystin-2 expression is developmentally regulated. Am J Physiol (1999) 1.02
Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not? Ann Rheum Dis (2006) 1.01
Acute intrinsic renal failure induced by indomethacin: role of prostaglandin synthetase inhibition. Mayo Clin Proc (1982) 1.01
CpG island in the region of an autosomal dominant polycystic kidney disease locus defines the 5' end of a gene encoding a putative proton channel. Proc Natl Acad Sci U S A (1991) 1.01
Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis. Aliment Pharmacol Ther (2007) 1.00
[Serious complications following (removal after) ingestion of a partial denture]. Ned Tijdschr Tandheelkd (2008) 1.00
Value of magnetic resonance angiography for the detection of intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (1993) 0.99
The liver in autosomal dominant polycystic kidney disease. Implications for pathogenesis. Arch Pathol Lab Med (1990) 0.99
Hereditary periodic fever and reactive amyloidosis. Clin Exp Med (2005) 0.99
Genotype and clinical care correlations in craniosynostosis: findings from a cohort of 630 Australian and New Zealand patients. Am J Med Genet C Semin Med Genet (2013) 0.98
Present and future of the nonsteroidal anti-inflammatory drugs in nephrology. Mayo Clin Proc (1982) 0.98
Heterozygous alpha-I antitrypsin deficiency as a co-factor in the development of chronic liver disease: a review. Neth J Med (2007) 0.98
Meclofenamate treatment of recurrent idiopathic nephrotic syndrome with focal segmental glomerulosclerosis after renal transplantation. Mayo Clin Proc (1984) 0.98
Colonoscopic polypectomy in children. J Pediatr Surg (1992) 0.98
Gastroenterological procedures among patients with disorders of hemostasis: evaluation and management recommendations. Gastrointest Endosc (1999) 0.97
Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver (1999) 0.96
Images in hepatology. Arterio-portal fistula causing recurrent variceal bleeding. J Hepatol (1998) 0.96
A case of esophageal duplication cyst with a 13-year follow-up period. Endoscopy (2005) 0.96
Compression of the inferior vena cava by right renal cysts: an unusual cause of IVC and/or iliofemoral thrombosis with pulmonary embolism in autosomal dominant polycystic kidney disease. Clin Nephrol (1998) 0.94
Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis (1994) 0.94
Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology (Oxford) (2005) 0.94
Intracranial cysts in autosomal dominant polycystic kidney disease. J Neurosurg (1995) 0.93